The UK and US have finalized a landmark commercial pact that will maintain zero levies on British pharmaceutical shipments entering the American market.
Agreement Details of the Accord
Under the terms of the agreement, the UK has committed to boost funding on medicines through the National Health Service (NHS). This pledge secures that tariffs on these crucial exports will remain at nothing for a period of the next three years.
This development is in response to recent warnings to hike import taxes on branded pharmaceutical imports, with figures floated reaching 100%.
"This arrangement between the UK reinforces the global environment for new treatments and brings much-needed fairness to transatlantic drug exports," a statement declared.
Commercial Importance
Medicines constitute one of the the United Kingdom's largest exports to the US, which is easily the biggest buyer for major British pharmaceutical firms.
Trade data reveal that in the year prior to September, the UK shipped medicines totaling billions to the US. This value made up a significant portion of British export trade in that timeframe.
"This agreement safeguards work, stimulates funding and sets the stage for the UK to establish itself as a worldwide center for medical research," a government official remarked.
Specific UK Commitments
The agreement includes several notable pledges from the UK:
- Price Threshold Increase: The UK will raise the affordability limit at which it deems new medicines to be unaffordable by a quarter.
- Boosted Medicine Funding: There is a target to raise overall NHS spending on drugs from 0.3% of GDP to 0.6 percent over the next decade.
- Rebate Cap: The amount manufacturers must return to the NHS to prevent overspending will be limited at 15%. In the past, repayments exceeded 20%.
Recent Tensions
The deal takes place against a protracted tension between the pharmaceutical industry and the British authorities over drug pricing and NHS adoption.
These tensions were intensified by arguments that US consumers were paying a premium for the same drugs than consumers in the Britain and the EU.
Recently, several large drug company projects in the UK have been paused or abandoned, while multi-billion-dollar investments have been announced toward US facilities.
The Science Minister stated that the NHS needed to spend more on medicines, noting that its expenditure on drugs had decreased as a percentage of its overall budget over the last ten years.
